Impaired angiogenesis due to inhibition of VEGF signaling decreases alveolar and vessel growth in the developing lung, suggesting that impaired VEGF signaling may contribute to decreased lung growth in bronchopulmonary dysplasia (BPD). Whether chronic treatment with exogenous VEGF improves lung structure in experimental models of BPD is unknown. The purpose of this study was to determine whether VEGF treatment would enhance alveolarization in infant rats after exposure to neonatal hyperoxia. Two day old Sprague Dawley rat pups were placed into a hyperoxia chamber (FiO2, 0.75) or room air for 12 days. At 14 days, rat pups were randomized to daily treatment with recombinant human VEGF 165 (rhVEGF; 20 µg/kg) im or vehicle (saline; controls). On day 22, rats were killed, and the heart and lungs were collected for study. In comparison with hyperoxic controls, rhVEGF treatment after hyperoxia increased RAC (11.8 + 0.5; p< 0.0001), decreased MLI (42.2 + 1.2; p < 0.0001), increased nodal point density (502 + 7; p<0.0005), and increased vessel density (23.2 + 0.4 vessels/hpf; p<0.001).We conclude that exposure of neonatal rats to hyperoxia impairs alveolarization and vessel density which persists despite recovery in room air, and that treatment with rhVEGF during the recovery period enhanced vessel growth and alveolarization in infant 2 rats. We speculate that persistent abnormalities of lung structure after hyperoxia may be partly due to impaired VEGF signaling.
Introduction
Bronchopulmonary dysplasia (BPD) is the chronic lung disease of infancy that follows ventilator and oxygen therapy for respiratory distress syndrome after premature birth (37). Although the mechanisms that cause BPD are not completely understood, surfactant deficiency, ventilator-induced lung injury, oxygen toxicity, and inflammation are important pathogenic factors (21). Traditionally, BPD has been characterized by severe chronic lung injury with striking fibrosis and cellular proliferation. With advancements in perinatal care including exogenous surfactant administration, improved ventilator management, and antenatal steroids, the clinical course and lung histology of BPD has changed. Infants with BPD now have less severe acute respiratory disease, and at autopsy, lung histology is characterized by arrested lung development including alveolar simplification and dysmorphic vascular growth (1, 18, 21, 37) .
Mechanisms that impair lung growth and cause persistent abnormalities in lung structure in premature infants with BPD remain poorly understood. Recently, experimental studies have shown that growth of the pulmonary circulation and alveolarization are closely coordinated, as demonstrated by findings that disruption of angiogenesis impairs lung structure (20) . Treatment of neonatal rats with anti-angiogenic agents, including fumagillin and thalidomide, decreases alveolarization and lung growth in infant rats, which is similar to the lung histology of BPD (20) . Treatment of newborn rats with the vascular endothelial growth factor (VEGF) receptor inhibitor, SU5416, also decreases alveolarization and vascular growth, suggesting that impaired VEGF signaling may contribute to abnormal lung structure after neonatal lung injury (20, 25) .
Interestingly, lung VEGF expression is decreased after hyperoxia in rabbits and in a primate model of BPD (30, 32) . Clinical studies further support the hypothesis that decreased VEGF expression contributes to the pathogenesis of BPD (4, 24) .
Previous animal studies have shown that exposure to hyperoxia in the neonatal period causes lung structural changes that are similar to the histology seen in human infants with BPD (39, 45, 46). Lung histology after hyperoxia is characterized by reduced complexity of the distal lung with decreased alveolar number and vascular growth (39, 40, 45, 46) . Mechanisms by which hyperoxia inhibits lung growth in BPD and potential therapeutic strategies to improve lung growth in BPD remain unknown.
Neonatal hyperoxia reduces lung VEGF mRNA and protein expression, suggesting that down-regulation of VEGF may contribute to the simplified lung structure seen in this model (23, 30, 31) . Recent studies further suggest that the reduction in VEGF protein persists beyond the hyperoxic injury and into the recovery period (27). However, whether late treatment with VEGF after hyperoxia can improve lung growth during recovery is unknown.
Therefore, we hypothesized that treatment with recombinant human VEGF (rhVEGF) protein would enhance alveolarization and vascular growth in infant rats during recovery from neonatal hyperoxia. To address this question, we studied the effects of rhVEGF treatment on lung structure during recovery from hyperoxia. We report that rhVEGF treatment improves alveolarization and vessel growth in infant rats during recovery after neonatal hyperoxia.
Methods

Animals
All procedures and protocols were approved by the Animal Care and Use
Committee at the University of Colorado Health Sciences Center. Pregnant SpragueDawley rats (SDR) were purchased (Harlan Laboratories, Indianapolis, IN) and maintained at Denver's altitude [1,600 meters; barometric pressure (PB), 630 mmHg; inspired oxygen pressure (PI O2 ), 122 mmHg] for at least 1 wk before giving birth. Pups were delivered naturally at term gestation. Litter size was standardized to 10 pups.
Animals were fed ad libitum and exposed to day-night cycles alternatively every 12 hours throughout the study period.
Study Design
Four groups of animals were used in these experiments with ten animals in each group ( Figure 1 ). All pups were maintained in room air for the first 24-36 hours of life to allow successful transition to postnatal life prior to randomization to study groups. On postnatal day 3, half of the animals were placed in 75% oxygen and half remained in room air for the next 12 days. On postnatal day 14, all animals were placed in room air.
The animals were randomly assigned to treatment with rhVEGF or saline. Half the animals in each litter were treated with intramuscular injections of rhVEGF at a dose of 20 micrograms (mcg) / kilogram (kg), and half were treated with normal saline injections for a total of seven days. The four study groups included hyperoxia + VEGF (H+V), hyperoxia + normal saline (H+NS), room air + VEGF (RA+V), and room air + normal saline (RA+NS). Litters of randomly divided rat pups and their dams were placed in plexiglass chambers containing 75% oxygen or room air. Oxygen concentrations were continuously monitored, and gas lines were filtered with charcoal and barium hydroxide to maintain CO 2 levels below 0.05%. Chambers were opened briefly (less than 10-15 minutes) for cleaning and injections. Animals were sacrificed on postnatal day 22 with intraperitoneal injections of pentobarbital (3 mg/kg body weight), and lung tissue was harvested for analysis.
Study Measurements
Body weight, lung weight, lung volume, right ventricular hypertrophy (RVH). Each animal was weighed prior to sacrifice. At autopsy, half the animals had lungs harvested for frozen tissue. Prior to freezing, wet lung weights were determined. The lungs of the remaining animals were fixed with paraformaldehyde and subsequently lung volume was determined by displacement of water. Additionally, the heart was resected through a midline sternotomy. The right ventricle (RV) was dissected from the left ventricle and septum (LV+S). The RV and LV+S were weighed separately and the ratios of RV to LV + S weights were determined as a standard assessment of RVH (12) .
Fixation of lung tissue. Rat lungs were prepared and fixed in situ at the time of sacrifice on day 22. A midline sternotomy was made. Lungs and heart were exposed. The left atrium was incised to allow drainage of perfusate. Phosphate buffered saline was then For assessment of skeletonization, six lung sections were selected in unbiased fashion. Images of each section were captured with a Magnafire digital camera through an Olympus IX 81 microscope, and were saved as PICT files. Using digital image processing, SoveaPro (Reindeer Graphics), the lung parenchyma was transformed into a skeleton of curved and straight line segments with nodal and end points as described by Tschanz and Burri (43). The number of nodal points per high power field was counted.
Immunohistochemistry and vessel volume density. Immunohistochemistry for factor
VIII was performed to identify vessels for morphometric assessment. Paraffin-embedded slides from paraformaldehyde-fixed tissue were deparaffinized in CitriSolv (Fisher Scientific; Pittsburgh, PA). The sections were rehydrated by serial immersions in 100% ethanol; 95% ethanol; 70% ethanol and water. Sections were digested with Proteinase K at a concentration of 500 µg/ml for 10 minutes at room temperature and then washed with phosphate buffered saline (PBS) with 2.7 mM KCl, 1.2 mM KH 2 PO 4 , 138 mM NaCl, and 8.1 mM Na 2 HPO 4 . Endogenous peroxidase activity was reduced by immersion in 3% hydrogen peroxide in methanol. After rinsing, sections were covered in 10% goat serum for 30 minutes, and incubated with rabbit anti-factor VIII antibody (1:1000) diluted in PBS with 1% BSA and 0.1% sodium azide for 60 minutes. After incubation, the sections were rinsed with PBS and incubated with biotin-labeled secondary antibody (diluted 1:200 in PBS with 2% goat serum) for 30 minutes. After incubation with the secondary antibody, the sections were rinsed with PBS, incubated in ABC complex (Vector) for 30 minutes at room temperature, rinsed in PBS and developed with diaminobenzidine (DAB) and hydrogen peroxide. Slides were lightly counter-stained with hematoxylin. The slides were then dehydrated by sequential immersion in 70% ethanol; 95% ethanol; 100% ethanol and CitriSolv before applying coverslips. Four lung sections were selected and captured by digital camera for analysis. The cells positive for factor VIII were stained brown. The number of factor VIII positive vessels per high power field was counted. The magnification used was 20X. Vessels immediately adjacent to large airways were excluded.
Statistical Analysis
Statistical comparison was made using analysis of variance and Fisher's protected least significant difference test with Statview software package (Abacus Concepts, Berkeley, CA). Differences were considered significant at P < 0.05. The results were presented as means ± standard error of mean (SEM).
Results
Body and lung weights and right ventricular hypertrophy:
Ten animals were in each study group. Body weights of the hyperoxia group were higher than body weights of the RA group at the beginning and at the end of the experiment, reflecting differences between birth weights of the pups from the different litters. However, VEGF treatment did not alter body weight within either the hyperoxia or RA groups. Lung weights were also higher in the hyperoxia group than in the RA group, but there was no difference in lung weights after VEGF or saline treatment within the hyperoxia or RA groups. The lung:body weight ratios were not different between VEGF saline treatments in either the hyperoxia or room air exposed groups. (TABLE 1) .
Lung histology and morphometrics:
In comparison with control animals (RA+NS), lung histology of animals exposed to hyperoxia (H+NS) was characterized by decreased septation, distal airspace enlargement, and a reduction in complexity (Figure 2 ). rhVEGF treatment during recovery after hyperoxia (H+VEGF) restored normal lung structure, which appears similar to the lung histology of RA raised controls. rhVEGF treatment of animals raised in RA (RA+VEGF) had no apparent effect on distal lung structure. Additionally, there was no histologic evidence of inflammation or edema in the VEGF treated animals.
To quantitate these differences, morphometric analysis was performed using three different techniques, including radial alveolar counts (RAC), mean linear intercepts (MLI), and skeletonization. As shown, RAC were lower in rats after recovery from p<0.01). There was no difference in vessel density between room air controls and room air animals treated with rhVEGF. Vessel density in the hyperoxia exposed group treated with rhVEGF was increased compared to the RA exposed saline treated animals and the RA exposed rhVEGF treated animals.
Discussion
We found that exposure of infant rats to hyperoxia impairs distal lung growth as characterized by reduced complexity with increased terminal airspace size, and decreased alveolar number, and vascular density, and that these changes persist despite recovery in room air. We further show that treatment with rhVEGF protein during recovery from hyperoxia improves lung architecture as demonstrated by increased septation and lung complexity with increased surface area, and vascular density. These findings further support the hypothesis that VEGF regulates angiogenesis and lung growth, and that inhibition of alveolarization following neonatal hyperoxia may be partly due to sustained impairment of VEGF signaling, which persists during infancy despite recovery in room air. This report is the first to demonstrate that VEGF treatment following neonatal hyperoxia improves recovery of lung structure after hyperoxia. Our results suggest that VEGF treatment enhances alveolarization and vascular growth after hyperoxic lung injury in infant rats and that this may improve lung growth and prevent development of BPD in premature infants.
Animal models of hyperoxic lung injury have been used to study the mechanisms that may have diverse roles including that of "permeability factor" by promoting early lung edema after injury, whereas VEGF may enhance recovery later in the course. Thus, the roles of VEGF may depend on timing and degree of endothelial -epithelial cell injury, as well as the degree of altered VEGF expression. This study examined the effects of exogenous rhVEGF treatment only during the recovery phase after hyperoxia. Although we did not directly measure lung edema, we found no difference in lung weight, body weight, and lung:body weight ratio after VEGF treatment. Body weights and lung weights were higher in the hyperoxic group compared to the room air group at the beginning and end of the study due to differences in initial birth weights between the hyperoxia and RA litters at the onset of the experiment.
Interestingly, MLI was increased and surface area, which is calculated from MLI, was reduced in RA animals treated with VEGF compared to RA animals treated with normal saline. This may reflect the differences between morphometric methods. RACs and nodal points by skeletonization did not reflect this difference. Alternatively, VEGF treatment in RA animals may alter lung structure, as suggested in previous studies, which showed that huge increases in lung VEGF gene expression in newborn mice can cause lung injury (26).
There are several potential limitations of this study. First, the body weights of the hyperoxia group were higher than the room air group at the start of the study due to differences between litters. However, VEGF did not alter body weight in either hyperoxia or room air. Second, term animals rather than premature animals were used in this model of BPD. However, the alveolar phase of lung development in the newborn rat occurs during the first three weeks of postnatal life (6, 7, 33) making this a useful time period during which to study mechanisms that impair lung growth. In addition, we studied the effects of VEGF treatment occurred during recovery after hyperoxia. Whether VEGF treatment during acute lung injury would have similar effects remains unknown.
Mechanisms through which VEGF increases vessel and alveolar growth in this model are uncertain and are currently under investigation. Finally, rhVEGF protein administration may have adverse systemic effects, but were not studied in this protocol.
In summary, we found that exposure of neonatal rats to hyperoxia results in impairment of alveolarization and vascular growth, which persists despite recovery in room air. We also report that rhVEGF treatment during the recovery period after neonatal hyperoxia restores normal lung architecture. Further studies are needed to determine the exact mechanisms by which VEGF treatment improves alveolarization and lung growth after neonatal hyperoxia, but these findings suggest that VEGF therapy may play a role in enhancing distal lung growth in BPD. Study design. On postnatal day 2, rat pups were exposed to hyperoxia or RA for 12 days.
On postnatal day 14 all animals were placed in RA. Rats were then randomized to daily injections of rhVEGF or normal saline for 7 days, and sacrificed on postnatal day 22 for study. Effects of rhVEGF treatment on mean linear intercepts (MLI) after hyperoxia in infant rats. Hyperoxia increased MLI which persists despite room air recovery. As shown, rhVEGF treatment during recovery from hyperoxia decreased MLI to levels seen in room air controls.
Figure 5
Effects of rhVEGF treatment after hyperoxia on lung complexity as assessed by skeletonization. As shown, hyperoxia decreased the number of nodal points per high power field (hpf). rhVEGF treatment during recovery increased nodal point density to levels seen in room air controls. Effects of rhVEGF treatment after hyperoxia on lung volume (upper panel) and calculated surface area (lower panel). As shown, there is no difference in lung volume between the four study groups. Surface area which is calculated as lung volume divided by MLI, is reduced after hyperoxia exposure. With rhVEGF treatment during recovery from hyperoxia lung surface area is restored to levels seen in RA controls. Effects of rhVEGF treatment on vessel density after hyperoxia in infant rats. Panel A represents lung histology stained with factor VIII of neonatal rats in normoxia at 22 days.
As shown, hyperoxia decreased lung growth (panel B). rhVEGF treatment had no effect on lung structure or vessel density of infant rats raised under normoxia (panel C). Effects of rhVEGF treatment on vascular density after hyperoxia in infant rats. With hyperoxia exposure there was a decrease in the number of cells which stained positive for factor VIII. rhVEGF treatment during recovery after hyperoxia exposure resulted in an increase in the number of factor VIII positive cells which is similar to room air controls. 
